Hasil Pencarian

Pediatric Dolutegravir: Securing Access to Dispersible Tablets for Children in the Asia-Pacific

US Food and Drug Administration (FDA) and the European Medicines Agency approved Dolutegravir for children with HIV

Experts publish recommendations on managing low-level but detectable HIV

...nt at very high viral load or very low CD4 counts. Integrase inhibitors such as dolutegravir or bictegravir may be protective against low-level viraemia showing the value of a higher barrier to resistance. To explain, th...

Para Ahli Menerbitkan Rekomendasi untuk Menangani Viral Load HIV yang Rendah tetapi Masih Terdeteksi

...l terhadap obat tersebut. Obat dengan penghalang resistensi tinggi antara lain: dolutegravir; bictegravir; dan darunavir yang diberikan dengan obat penguat. Dolutegravir terdapat dalam sejumlah kombinasi pengobatan, seda...

Penggunaan integrase inhibitor dapat meningkatkan risiko diabetes pada orang dengan HIV

...siko kejadian kardiovaskular utama.   Integrase inhibitor – termasuk dolutegravir dan bictegravir – direkomendasikan untuk pengobatan lini pertama HIV atau sebagai pilihan peralihan bagi orang yang sudah...

Switching to an integrase inhibitor can raise diabetes risk in people with HIV

...sed risk of major cardiovascular events. Integrase inhibitors – including dolutegravir and bictegravir – are recommended for first-line treatment of HIV or as a switch option for people already taking another...

Cancer Screening Gaps Leave People With HIV at Elevated Risk

... regimen adjustments as needed. Regimens based on integrase inhibitors, such as dolutegravir or bictegravir, tend to have fewer drug interactions than protease inhibitor-based regimens. “Systematic review of intera...

Kenaikan berat badan lebih sedikit dengan Dovato daripada Biktarvy

...pada Biktarvy Oleh: Keith Alcorn, 3 November 2025 Peralihan ke rejimen dua obat dolutegravir/lamivudin (Dovato) menghasilkan kenaikan berat badan yang jauh lebih sedikit setelah 96 minggu dibandingkan dengan peralihan ke...

Less weight gain with Dovato than Biktarvy

Switching to a two-drug regimen of dolutegravir / lamivudine (Dovato) resulted in significantly less weight gain after 96 weeks compared to a switch to tenofovir alafenamide / emtricitabine / bictegravir (Biktarvy), the ...

Hepatitis B reactivation is rare after switching from tenofovir, two European studies show

...on in people with past hepatitis B exposure. As such regimens – including dolutegravir/lamivudine and cabotegravir/rilpivirine – are more widely used, there have been concerns that hepatitis B reactivation ma...